Drug intelligence / Profile preview

SAR245409 + erlotinib

Development stage: Unknown
Lead developer: Sanofi
Modality: Small Molecules
Administration: Oral

Overview

SAR245409 + erlotinib is a combination therapy consisting of SAR245409 (voxtalisib/XL765), a pan-class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor, and erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. This combination targets both the PI3K/mTOR and EGFR signaling pathways, which are commonly dysregulated in cancer cells. The combination has been studied in phase I clinical trials for patients with advanced solid tumors, particularly those with non-small cell lung cancer (NSCLC) who had previously received EGFR inhibitor therapy.

Other names: Voxtalisib + erlotinib

Targets

mTOR (Mammalian target of rapamycin kinase)EGFR T790M (Epidermal growth factor receptor T790M mutant)DNA-PK (DNA-dependent protein kinase)

Beyond the preview

Go deeper on SAR245409 + erlotinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SAR245409 + erlotinib.

Explore the full profile